

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Canntab Therapeutics Limited (the "Issuer").

Trading Symbol: PILL

Number of Outstanding Listed Securities: 25,306,601

Date: December 6, 2018

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On November 14th the issuer released a corporate update. Canntab Therapeutics is a company with a clear vision of becoming the leader in solid oral dosage formulation of cannabis. Their unique products offer advantages to the medical community, patients, adult use consumers and governments. Canntab is pleased to provide this corporate update to its shareholders.

This includes;

- *An excellent capitalized structure of approximately 28.6M shares outstanding on a fully diluted basis with no need for short term financing of its business plan.*
- *A strong intellectual property portfolio with 13 patents pending in the United States and Canada pertaining to the formulation of tablets including instant release, extended release, flash melt and bi-layered. The products will be available in 2.5mg, 5mg and 10mg tablets.*
- *An application to become a Licensed Producer (Non Grower) under the Access to Cannabis for Medical Purposes Regulations and has confirmation from Health Canada that its application had been received.*
- *A notice that it is now a part of the Composite Index of the Canadian Securities Exchange as part of their quarterly rebalancing.*
- *Reaching a milestone in its development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC, OTCQX: EMMBF). Dissolution testing indicated that the Extended Release Tablets released cannabinoids consistently over a 12-hour period. Given these positive test results, Canntab is manufacturing pivotal batches of these tablets for further clinical testing. This will lead to the filing of dossiers with regulatory agencies around the world for approval of Canntab's unique solid oral dose delivery systems.*
- *Announcement of the signing of a non-binding Letter of Intent with NewCanna S.A.S of Bogota, Colombia for the establishment of a significant bi-lateral relationship covering the sale and distribution of Canntab's products in Colombia, Chile, Paraguay and Spain with a one-time, non-refundable license fee (\$2-million US) payable to Canntab by NewCanna.*

- *Announcement of the signing of a non-binding Letter of Intent with Labsco Promedic SA for the establishment of a joint venture relationship covering, on an exclusive basis, the sales and distribution of Canntab products in Mexico.*
2. Provide a general overview and discussion of the activities of management.
None other than as described above.
 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
None other than as described in paragraph 1 above.
 4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
N/A
 5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
None other than as described in paragraph 1 above.
 6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
N/A
 7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
N/A
 8. Describe the acquisition of new customers or loss of customers.
N/A
 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
N/A
 10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
N/A

N/A

- 11. Report on any labour disputes and resolutions of those disputes if applicable.
N/A
- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
N/A
- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
N/A
- 14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common Shares	21,900	Exercise of Broker Warrants	N/A

- 15. Provide details of any loans to or by Related Persons.
N/A
- 16. Provide details of any changes in directors, officers or committee members.
N/A
- 17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer, which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 6, 2018.

Richard Goldstein
 Name of Director or Senior
 Officer
signed "Richard Goldstein"
 Signature
 CFO
 Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer		November, 2018	YY/MM/DD
Canntab Therapeutics Limited.			18/12/04
Issuer Address			
1 Adelaide Street East			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Toronto, ON M5C 2V9		()	416-957-6303
Contact Name		Contact Position	Contact Telephone
Richard Goldstein		CFO	No. 416-957-6303
Contact Email Address		Web Site Address	
richard@firstrepubliccapital.com		www.canntab.ca	